View ValuationArrowhead Pharmaceuticals 향후 성장Future 기준 점검 2/6Arrowhead Pharmaceuticals은 연간 수입과 매출이 각각 18.5%와 36.5% 증가할 것으로 예상되고 EPS는 연간 22%만큼 증가할 것으로 예상됩니다.핵심 정보18.5%이익 성장률21.99%EPS 성장률Biotechs 이익 성장0%매출 성장률36.5%향후 자기자본이익률n/a애널리스트 커버리지Good마지막 업데이트26 Feb 2025최근 향후 성장 업데이트No longer forecast to breakeven Dec 01모든 업데이트 보기Recent updatesArrowhead Pharmaceuticals Inc Receives Tga Approval of Redemplo (Plozasiran) in Australia Expanding Global Access for Patients with Familial Chylomicronemia SyndromeMay 03Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval Of REDEMPLO (Plozasiran) To Reduce Triglycerides In Adults With Familial Chylomicronemia Syndrome In EuropeApr 26Arrowhead Pharmaceuticals Presents New Long-Term Efficacy And Safety Data For Plozasiran Across A Spectrum Of HypertriglyceridemiaMar 28Arrowhead Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 05, 2026Feb 06Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 19, 2026Jan 28Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed HyperlipidemiaJan 27Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.998502 million.Jan 08Arrowhead Pharmaceuticals Announces Nmpa Approval of Redemplo (Plozasiran) for Familial Chylomicronemia Syndrome in ChinaJan 07+ 2 more updatesArrowhead Pharmaceuticals Announces Health Canada Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia SyndromeJan 05Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other TauopathiesDec 09Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe HypertriglyceridemiaDec 02Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia SyndromeNov 19Arrowhead Pharmaceuticals, Inc. Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed HyperlipidemiaOct 07Ionis Pharmaceuticals, Inc. Files Complaint for Patent Infringement Against Arrowhead Pharmaceuticals, IncSep 13Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other TauopathiesSep 10Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial HypercholesterolemiaJul 08Arrowhead Pharmaceuticals Completes Enrollment in Shasta-3, Shasta-4, and Muir-3 Phase 3 Studies of PlozasiranJun 24Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of Aro-Alk7 for the Treatment of ObesityJun 02Arrowhead Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 13, 2025Apr 16Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA NephropathyMar 10Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic DiseasesMar 06Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)Feb 28Arrowhead Pharmaceuticals, Inc. Presents Preclinical Data on Aro-Alk7 for Treatment of ObesityFeb 26Arrowhead Pharmaceuticals, Inc. Appoints Douglas Ingram as DirectorFeb 08Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2025Jan 30Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia SyndromeJan 18Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of ObesityDec 24Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated DiseasesDec 11Insufficient new directors Dec 05Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of ObesityDec 03Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of DirectorsNov 26Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia SyndromeNov 19+ 1 more updateArrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia SyndromeSep 03Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical StudiesAug 15Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes TrialJun 26Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia SyndromeJun 05Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with AsthmaMay 22Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney DiseaseApr 24Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & ExpoApr 09Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic DystrophyMar 08Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024Jan 27Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024Jan 22Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.Jan 05Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic DystrophyNov 29Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023Nov 15Insufficient new directors Jul 17Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1Jun 28Insufficient new directors Jun 10Chairman of the Board recently sold Mex$525k worth of stock Mar 06Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 ResultsFeb 16+ 1 more updateFirst quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022) Feb 07Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary FibrosisFeb 03Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023Jan 31Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.Jan 22Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver DiseaseJan 10Insufficient new directors Jan 01Full year 2022 earnings released: US$1.67 loss per share (vs US$1.36 loss in FY 2021) Dec 01No longer forecast to breakeven Dec 01Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021) Aug 05이익 및 매출 성장 예측BMV:ARWR * - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/2027290-434-357-21399/30/2026219-502-411-356149/30/2025291-3262802971612/31/20243-640-572-491N/A9/30/20244-599-604-463N/A6/30/202420-539-533-352N/A3/31/202435-471-470-257N/A12/31/2023182-297-403-196N/A9/30/2023241-205-331-154N/A6/30/2023256-181-342-197N/A3/31/2023273-150-353-245N/A12/31/2022278-155-236-150N/A9/30/2022243-176-189-136N/A6/30/2022250-154-120-91N/A3/31/2022263-112-75-52N/A12/31/2021144-183124149N/A9/30/2021138-141148171N/A6/30/2021108-126167184N/A3/31/202189-110165181N/A12/31/202080-103-123-111N/A9/30/202088-85-108-96N/A6/30/2020124-24-89-71N/A3/31/202013910-46-27N/A12/31/201916453-34-19N/A9/30/201916968161173N/A6/30/201913746152157N/A3/31/20199510130132N/A12/31/201847-29134136N/A9/30/201816-54N/A-47N/A6/30/201814-54N/A-54N/A3/31/201822-44N/A-50N/A12/31/201731-35N/A-49N/A9/30/201731-34N/A-24N/A6/30/201723-46N/A-25N/A3/31/201713-60N/A-33N/A12/31/20164-75N/A-33N/A9/30/20160-82N/A-64N/A6/30/20160-84N/A-66N/A3/31/20160-81N/A-61N/A12/31/20150-89N/A-63N/A9/30/20150-92N/A-66N/A6/30/20150-90N/A-65N/A3/31/20150-85N/A-61N/A12/31/20140-71N/A-53N/A9/30/20140-59N/A-35N/A6/30/20140-50N/A-30N/A3/31/20140-44N/A-25N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ARWR * 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: ARWR * 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: ARWR * 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: ARWR * 의 수익(연간 36.5%)이 MX 시장(연간 6.3%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: ARWR * 의 수익(연간 36.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ARWR *의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/03/04 22:41종가2024/12/05 00:00수익2024/12/31연간 수익2024/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Arrowhead Pharmaceuticals, Inc.는 28명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ying HuangBarclaysWilliam PickeringBernsteinJason Matthew GerberryBofA Global Research25명의 분석가 더 보기
Arrowhead Pharmaceuticals Inc Receives Tga Approval of Redemplo (Plozasiran) in Australia Expanding Global Access for Patients with Familial Chylomicronemia SyndromeMay 03
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval Of REDEMPLO (Plozasiran) To Reduce Triglycerides In Adults With Familial Chylomicronemia Syndrome In EuropeApr 26
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy And Safety Data For Plozasiran Across A Spectrum Of HypertriglyceridemiaMar 28
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed HyperlipidemiaJan 27
Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.998502 million.Jan 08
Arrowhead Pharmaceuticals Announces Nmpa Approval of Redemplo (Plozasiran) for Familial Chylomicronemia Syndrome in ChinaJan 07+ 2 more updates
Arrowhead Pharmaceuticals Announces Health Canada Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia SyndromeJan 05
Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other TauopathiesDec 09
Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe HypertriglyceridemiaDec 02
Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia SyndromeNov 19
Arrowhead Pharmaceuticals, Inc. Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed HyperlipidemiaOct 07
Ionis Pharmaceuticals, Inc. Files Complaint for Patent Infringement Against Arrowhead Pharmaceuticals, IncSep 13
Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other TauopathiesSep 10
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial HypercholesterolemiaJul 08
Arrowhead Pharmaceuticals Completes Enrollment in Shasta-3, Shasta-4, and Muir-3 Phase 3 Studies of PlozasiranJun 24
Arrowhead Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 13, 2025Apr 16
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA NephropathyMar 10
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic DiseasesMar 06
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)Feb 28
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia SyndromeJan 18
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of ObesityDec 24
Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated DiseasesDec 11
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of ObesityDec 03
Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia SyndromeNov 19+ 1 more update
Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia SyndromeSep 03
Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical StudiesAug 15
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes TrialJun 26
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia SyndromeJun 05
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with AsthmaMay 22
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney DiseaseApr 24
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & ExpoApr 09
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic DystrophyMar 08
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024Jan 22
Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.Jan 05
Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic DystrophyNov 29
Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023Nov 15
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1Jun 28
Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 ResultsFeb 16+ 1 more update
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary FibrosisFeb 03
Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.Jan 22
Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver DiseaseJan 10